Hcw Biologics INC 10-Q quarterly reports

HCW Biologics Inc. filed its Q2 2026 Form 10-Q, detailing a net loss of $5.2 million, continued operating losses, and substantial doubt about its ability to continue as a going concern, alongside progress in clinical development and licensing agreements.

HCW Biologics Inc. has amended its Q1 2026 report to correct an earnings per share calculation error, while simultaneously reporting a significant increase in revenue driven by licensing agreements.

HCW Biologics reported a reduced net loss for Q3 2025 but faces substantial doubt about its going concern ability, a Nasdaq compliance deadline, and ongoing legal and construction challenges.

HCW Biologics reports reduced net losses and improved equity, but faces ongoing liquidity challenges, legal disputes, and a key license suspension while advancing its immunotherapy pipeline.

HCW Biologics faces going concern doubts despite Q1 revenue increase and clinical advancements, focusing on financing and Nasdaq compliance.

HCW Biologics' Q3 2024 report reveals ongoing financial strain, strategic shifts following a legal settlement, and a focus on securing future funding.

HCW Biologics faced a challenging second quarter of 2024, marked by a significant legal settlement, a criminal fraud incident, and ongoing financial concerns, while continuing to advance its clinical programs.

HCW Biologics saw a significant increase in revenue in Q1 2024 compared to Q1 2023, but also experienced a substantial increase in net losses and ongoing concerns about its ability to continue as a going concern.